469 related articles for article (PubMed ID: 25196228)
1. Correlation of quantitative diffusion-weighted and dynamic contrast-enhanced MRI parameters with prognostic factors in prostate cancer.
Chung MP; Margolis D; Mesko S; Wang J; Kupelian P; Kamrava M
J Med Imaging Radiat Oncol; 2014 Oct; 58(5):588-94. PubMed ID: 25196228
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: correlation with histopathology.
Styles C; Ferris N; Mitchell C; Murphy D; Frydenberg M; Mills J; Pedersen J; Bergen N; Duchesne G
J Med Imaging Radiat Oncol; 2014 Aug; 58(4):439-48. PubMed ID: 24935089
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.
Oto A; Yang C; Kayhan A; Tretiakova M; Antic T; Schmid-Tannwald C; Eggener S; Karczmar GS; Stadler WM
AJR Am J Roentgenol; 2011 Dec; 197(6):1382-90. PubMed ID: 22109293
[TBL] [Abstract][Full Text] [Related]
4. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.
Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B
J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
Vilanova JC; Barceló-Vidal C; Comet J; Boada M; Barceló J; Ferrer J; Albanell J
AJR Am J Roentgenol; 2011 Jun; 196(6):W715-22. PubMed ID: 21606259
[TBL] [Abstract][Full Text] [Related]
6. Detection of prostate cancer in peripheral zone: comparison of MR diffusion tensor imaging, quantitative dynamic contrast-enhanced MRI, and the two techniques combined at 3.0 T.
Li C; Chen M; Li S; Zhao X; Zhang C; Luo X; Zhou C
Acta Radiol; 2014 Mar; 55(2):239-47. PubMed ID: 23892233
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
8. Quantitative diffusion-weighted imaging and dynamic contrast-enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients.
Yuan Q; Costa DN; Sénégas J; Xi Y; Wiethoff AJ; Rofsky NM; Roehrborn C; Lenkinski RE; Pedrosa I
J Magn Reson Imaging; 2017 Mar; 45(3):908-916. PubMed ID: 27442039
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy.
Woodfield CA; Tung GA; Grand DJ; Pezzullo JA; Machan JT; Renzulli JF
AJR Am J Roentgenol; 2010 Apr; 194(4):W316-22. PubMed ID: 20308476
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.
De Visschere P; Lumen N; Ost P; Decaestecker K; Pattyn E; Villeirs G
Clin Radiol; 2017 Jan; 72(1):23-32. PubMed ID: 27726850
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
[TBL] [Abstract][Full Text] [Related]
12. Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy.
Vasarainen H; Lahdensuo K; Savolainen R; Ruutu M; Taari K; Rannikko A
Scand J Urol; 2013 Dec; 47(6):456-61. PubMed ID: 23327661
[TBL] [Abstract][Full Text] [Related]
13. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy.
Jambor I; Kähkönen E; Taimen P; Merisaari H; Saunavaara J; Alanen K; Obsitnik B; Minn H; Lehotska V; Aronen HJ
J Magn Reson Imaging; 2015 May; 41(5):1394-404. PubMed ID: 24956412
[TBL] [Abstract][Full Text] [Related]
14. Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage.
Wu X; Reinikainen P; Kapanen M; Vierikko T; Ryymin P; Kellokumpu-Lehtinen PL
Contrast Media Mol Imaging; 2018; 2018():3181258. PubMed ID: 30327584
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging.
Tamada T; Sone T; Higashi H; Jo Y; Yamamoto A; Kanki A; Ito K
AJR Am J Roentgenol; 2011 Sep; 197(3):664-70. PubMed ID: 21862809
[TBL] [Abstract][Full Text] [Related]
16. Correlation of gleason scores with magnetic resonance diffusion tensor imaging in peripheral zone prostate cancer.
Li L; Margolis DJ; Deng M; Cai J; Yuan L; Feng Z; Min X; Hu Z; Hu D; Liu J; Wang L
J Magn Reson Imaging; 2015 Aug; 42(2):460-7. PubMed ID: 25469909
[TBL] [Abstract][Full Text] [Related]
17. The Utility of Diffusion-Weighted Imaging and Perfusion Magnetic Resonance Imaging Parameters for Detecting Clinically Significant Prostate Cancer.
Cindil E; Oner Y; Sendur HN; Ozdemir H; Gazel E; Tunc L; Cerit MN
Can Assoc Radiol J; 2019 Nov; 70(4):441-451. PubMed ID: 31561925
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology.
Isebaert S; Van den Bergh L; Haustermans K; Joniau S; Lerut E; De Wever L; De Keyzer F; Budiharto T; Slagmolen P; Van Poppel H; Oyen R
J Magn Reson Imaging; 2013 Jun; 37(6):1392-401. PubMed ID: 23172614
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T.
Thörmer G; Otto J; Horn LC; Garnov N; Do M; Franz T; Stolzenburg JU; Moche M; Kahn T; Busse H
Acta Radiol; 2015 Jan; 56(1):121-8. PubMed ID: 24504488
[TBL] [Abstract][Full Text] [Related]
20. Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer.
Chen YJ; Chu WC; Pu YS; Chueh SC; Shun CT; Tseng WY
J Magn Reson Imaging; 2012 Oct; 36(4):912-9. PubMed ID: 22711415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
